The relationship between mercury and autism: A comprehensive review and discussionRelevance of Neuroinflammation and Encephalitis in AutismAn evaluation of the role and treatment of elevated male hormones in autism spectrum disordersEvidence of parallels between mercury intoxication and the brain pathology in autismNew science challenges old notion that mercury dental amalgam is safeThimerosal: clinical, epidemiologic and biochemical studiesQuadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database.A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review.A case-control study of serious autoimmune adverse events following hepatitis B immunization.A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events.A longitudinal ecological study of household firearm ownership and firearm-related deaths in the United States from 1999 through 2014: A specific focus on gender, race, and geographic variables.Abnormal Brain Connectivity Spectrum Disorders Following Thimerosal Administration: A Prospective Longitudinal Case-Control Assessment of Medical Records in the Vaccine Safety Datalink.Methodological issues and evidence of malfeasance in research purporting to show thimerosal in vaccines is safe.A prospective study of thimerosal-containing Rho(D)-immune globulin administration as a risk factor for autistic disorders.The true story of pertussis vaccination: a sordid legacy?Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication.A dose-response relationship between organic mercury exposure from thimerosal-containing vaccines and neurodevelopmental disordersA Comparison of the Autism Treatment Evaluation Checklist (ATEC) and the Childhood Autism Rating Scale (CARS) for the Quantitative Evaluation of AutismThe potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity.Thimerosal-containing hepatitis B vaccination and the risk for diagnosed specific delays in development in the United States: a case-control study in the vaccine safety datalinkAn assessment of downward trends in neurodevelopmental disorders in the United States following removal of Thimerosal from childhood vaccines.A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism.A prospective study of prenatal mercury exposure from maternal dental amalgams and autism severity.Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink.Biomarkers of environmental toxicity and susceptibility in autism.A comprehensive review of mercury provoked autism.A case-control study evaluating the relationship between thimerosal-containing haemophilus influenzae type b vaccine administration and the risk for a pervasive developmental disorder diagnosis in the United States.Serious neurological conditions following pertussis immunization: an analysis of endotoxin levels, the vaccine adverse events reporting system (VAERS) database and literature review.Mitochondrial dysfunction, impaired oxidative-reduction activity, degeneration, and death in human neuronal and fetal cells induced by low-level exposure to thimerosal and other metal compoundsA review of hepatitis B vaccination.A review of the Vaccine Adverse Event Reporting System database.A Prospective Longitudinal Assessment of Medical Records for Diagnostic Substitution among Subjects Diagnosed with a Pervasive Developmental Disorder in the United States.A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders.A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disorders.Hair toxic metal concentrations and autism spectrum disorder severity in young children.The temporal relationship between RotaTeq immunization and intussusception adverse events in the Vaccine Adverse Event Reporting System (VAERS).A quantitative evaluation of brain dysfunction and body-burden of toxic metals.A prospective Cross-sectional Cohort Assessment of Health, Physical, and Behavioral Problems in Autism Spectrum Disorders.Thimerosal-Preserved Hepatitis B Vaccine and Hyperkinetic Syndrome of ChildhoodA clinical trial of glutathione supplementation in autism spectrum disorders
P50
Q26740476-DD83C0DB-A488-4642-AC1D-F4F10AE188E9Q26772834-AAF679D8-F29E-4C82-B0FA-6CF86D539EEDQ26820611-1F1636E2-0EC0-42DE-B24D-35D528D68A70Q27003899-EF1697D4-D6D0-4E45-AF21-90C85292A3BAQ27006894-8D190D81-1EBF-4367-85FF-716A577AF020Q28087764-356D81F3-9C70-4BE2-AD0A-5A2E34BFBD41Q33167424-7DA5B2AE-5B03-4D2F-81AF-816711F2E64AQ33364449-E4378F4C-CA86-492A-91A9-93C6EC33FB09Q33368806-64CC199F-2D56-4FAA-BF44-FDEE9F057DB1Q33419464-9E17314C-4A50-41D2-82B3-4488E51B4DA1Q33599676-1385C419-C50C-4317-A5D6-ACB07A4FC01DQ33693281-6CC646D0-FD98-4BBE-BBB5-CC5FAC604700Q33787078-CDBEF2B7-482C-4BCA-A446-65EA86696FC0Q34005494-8D15D87C-9096-4542-AADC-35F7A12C73F0Q34147718-C6B2AC29-40FD-41D4-A2F4-A2DC84C89DF7Q34201117-0B5DE082-C002-4D83-92DC-AB2F8305D883Q34348131-73A859BA-D411-42A3-84BF-85F836921A4DQ34361783-424E5472-B031-495A-96B6-C7119A7032F2Q34404907-0415E8F9-BFB1-4461-B7F2-FB941886DD42Q34432373-8E5C0CA6-D06F-4C02-9A4E-6D925B233FA2Q34531836-43FB410E-F840-411B-A781-0B9FD3E46BE3Q34545767-BC9F46FD-FFA7-490A-B25C-E592ABE890C9Q34609811-EE81796E-7451-4584-B237-4AC247314A78Q34778856-34B4C6A5-A829-4ADA-B065-57873F3F2B3AQ34837538-3EFB842D-1610-4D15-971F-2F5AC9C1F229Q34910408-6E653B90-78FA-4F74-9D79-8F70771C7038Q34978632-BC632955-B51F-463C-B707-277BEB1BA181Q35066676-D66FDD8C-73CF-47EE-9CCD-37E87D929528Q35095201-CF44B761-B0EC-49F4-9AFF-9D675F00E6E9Q35194402-873E2C9B-F9E4-4647-AAB7-677F0D58058BQ35688205-F46294CB-1E88-415F-9FA1-18B13E0DB09DQ36146224-67B21BEF-2A34-49B7-B059-B3197665414EQ36516455-73033D47-5399-4B5A-A190-51F2124172CAQ36529546-DCDA67A2-661B-47D4-A36D-990F0B142B05Q36538671-D963D0DB-C6E6-436D-8A25-5CF72D844EF5Q36576880-2E80C8C8-2E54-40F9-A43A-6DEAB4E313B6Q36577547-55F2F60E-78DA-44CB-A492-604E50B1A9B8Q36594280-A3735CC3-C0D8-4D75-B440-00954FC30107Q36735514-90015196-768B-4CAC-8DB3-B87F95F6E562Q36771431-8194A613-CAA6-4AA8-8B83-7D532FA25CDF
P50
description
American geneticist
@en
Amerikaans klinische genetica
@nl
amerikansk genetiker
@nb
genetista estadounidense
@es
jeneticiste american
@lfn
usona genetikisto
@eo
name
Mark Geier
@ast
Mark Geier
@ca
Mark Geier
@de
Mark Geier
@en
Mark Geier
@es
Mark Geier
@fr
Mark Geier
@it
Mark Geier
@nb
Mark Geier
@nl
Mark Geier
@sl
type
label
Mark Geier
@ast
Mark Geier
@ca
Mark Geier
@de
Mark Geier
@en
Mark Geier
@es
Mark Geier
@fr
Mark Geier
@it
Mark Geier
@nb
Mark Geier
@nl
Mark Geier
@sl
altLabel
Mark R. Geier
@nb
Mark Robin Geier
@nb
prefLabel
Mark Geier
@ast
Mark Geier
@ca
Mark Geier
@de
Mark Geier
@en
Mark Geier
@es
Mark Geier
@fr
Mark Geier
@it
Mark Geier
@nb
Mark Geier
@nl
Mark Geier
@sl
P106
P244
P2038
Mark_Geier
P21
P214
69152682527123310894
P244
no2005103232
P31
P551
P569
1948-01-01T00:00:00Z
P735
P7859
viaf-69152682527123310894